271 related articles for article (PubMed ID: 22014573)
1. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies.
Schaefer G; Haber L; Crocker LM; Shia S; Shao L; Dowbenko D; Totpal K; Wong A; Lee CV; Stawicki S; Clark R; Fields C; Lewis Phillips GD; Prell RA; Danilenko DM; Franke Y; Stephan JP; Hwang J; Wu Y; Bostrom J; Sliwkowski MX; Fuh G; Eigenbrot C
Cancer Cell; 2011 Oct; 20(4):472-86. PubMed ID: 22014573
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
[TBL] [Abstract][Full Text] [Related]
3. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
4. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells.
Chang C; Takayanagi A; Yoshida T; Shimizu N
Exp Cell Res; 2013 May; 319(8):1146-55. PubMed ID: 23499740
[TBL] [Abstract][Full Text] [Related]
6. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
7. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
[TBL] [Abstract][Full Text] [Related]
8. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
11. An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling.
Sala G; Traini S; D'Egidio M; Vianale G; Rossi C; Piccolo E; Lattanzio R; Piantelli M; Tinari N; Natali PG; Muraro R; Iacobelli S;
Oncogene; 2012 Mar; 31(10):1275-86. PubMed ID: 21822299
[TBL] [Abstract][Full Text] [Related]
12. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
13. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
[TBL] [Abstract][Full Text] [Related]
14. Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.
Bourillon L; Demontoy S; Lenglet A; Zampieri A; Fraisse J; Jarlier M; Boissière-Michot F; Perrochia H; Rathat G; Garambois V; Bonnefoy N; Michaud HA; Chardès T; Tosi D; Pèlegrin A; Azria D; Larbouret C; Bourgier C
Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):1039-1051. PubMed ID: 31959545
[TBL] [Abstract][Full Text] [Related]
15. Small-animal SPECT/CT of HER2 and HER3 expression in tumor xenografts in athymic mice using trastuzumab Fab-heregulin bispecific radioimmunoconjugates.
Razumienko EJ; Scollard DA; Reilly RM
J Nucl Med; 2012 Dec; 53(12):1943-50. PubMed ID: 23096164
[TBL] [Abstract][Full Text] [Related]
16. RETRACTED: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody.
Hu S; Dai H; Zhang T; Fu W; Berezov SD; Chen C; Jorissen D; Takeda H; Bethune AN
Cancer Lett; 2015 Feb; 357(1):374-383. PubMed ID: 25434797
[TBL] [Abstract][Full Text] [Related]
17. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
18. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation.
Talavera A; Friemann R; Gómez-Puerta S; Martinez-Fleites C; Garrido G; Rabasa A; López-Requena A; Pupo A; Johansen RF; Sánchez O; Krengel U; Moreno E
Cancer Res; 2009 Jul; 69(14):5851-9. PubMed ID: 19584289
[TBL] [Abstract][Full Text] [Related]
19. Immunology. Two-in-one designer antibodies.
Parren PW; Burton DR
Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
[No Abstract] [Full Text] [Related]
20. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]